Bev

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024

“In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.

Key Points: 
  • “In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.
  • We believe this mechanism explains the strong clinical results we have seen in both our Phase 1b/2 and ONSEMBLE second-line RAS-mutated mCRC clinical trials.
  • The abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR.
  • Following presentation, the posters will be posted to the " Scientific Presentations " section of the Cardiff Oncology website.

Li Auto Inc. February 2024 Delivery Update

Retrieved on: 
Friday, March 1, 2024

BEIJING, China, March 01, 2024 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that the Company delivered 20,251 vehicles in February 2024, up 21.8% year over year.

Key Points: 
  • BEIJING, China, March 01, 2024 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that the Company delivered 20,251 vehicles in February 2024, up 21.8% year over year.
  • The cumulative deliveries of Li Auto vehicles reached 684,780 as of the end of February 2024.
  • We are scheduled to officially launch the long-expected Li MEGA and 2024 Li L series models at our spring launch event this afternoon.
  • Additionally, our 2024 Li L7, Li L8, and Li L9 models will come equipped with enhanced functions and features to better serve our family users.

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024

New clinical data from discontinued second-line randomized ONSEMBLE trial provides further evidence of onvansertib’s improvement of the efficacy for standard of care therapy in bev naïve patients.

Key Points: 
  • New clinical data from discontinued second-line randomized ONSEMBLE trial provides further evidence of onvansertib’s improvement of the efficacy for standard of care therapy in bev naïve patients.
  • Contingent upon the results, Cardiff Oncology will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent.
  • Full Year 2023 Financial Results:
    As of December 31, 2023, Cardiff Oncology had approximately $75 million in cash, cash equivalents, and short-term investments.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 29, 2024.

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Retrieved on: 
Thursday, February 29, 2024

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today provided a clinical update on the first release of data from its second-line RAS-mutated metastatic colorectal cancer (mCRC) ONSEMBLE trial. Although the Phase 2 ONSEMBLE trial was discontinued as part of the company’s shift to a first-line mCRC program, it enrolled 23 patients randomized across three arms prior to closing the trial to new enrollment. The 23 enrolled patients continued treatment per protocol. The clinical data repeats the efficacy findings of onvansertib in bev naïve patients seen in the company’s earlier Phase 1b/2 KRAS-mutated mCRC trial.

Key Points: 
  • Although the Phase 2 ONSEMBLE trial was discontinued as part of the company’s shift to a first-line mCRC program, it enrolled 23 patients randomized across three arms prior to closing the trial to new enrollment.
  • The clinical data repeats the efficacy findings of onvansertib in bev naïve patients seen in the company’s earlier Phase 1b/2 KRAS-mutated mCRC trial.
  • “The randomized data from the ONSEMBLE trial further validates the opportunity for onvansertib in the first-line RAS-mutated mCRC setting.
  • We look forward to sharing the topline results of our first-line CRDF-004 trial in mid-2024.”
    In August 2023, Cardiff Oncology discontinued enrollment in the second-line ONSEMBLE trial to focus on its new lead program in first-line RAS-mutated mCRC.

Beam Global Granted European Patent for Thermal Management Technology that Makes Lithium-ion Batteries Safer

Retrieved on: 
Thursday, February 22, 2024

The European Patent Office granted European Patent No.

Key Points: 
  • The European Patent Office granted European Patent No.
  • We now have various patents covering our battery technology and innovations in the US, China, the European Union, France, Germany and India,” said Desmond Wheatley, Beam Global’s CEO.
  • Beam Global’s patented battery solutions are designed to make this dominant technology safer.
  • Early 2024 data shows global EV sales up 69% in January 2024 compared to January 2023.

BEV Shoppers Lack Awareness of Vehicle-to-Home, Vehicle-to-Grid Capabilities

Retrieved on: 
Tuesday, February 20, 2024

When asked about vehicle-to-home (V2H) energy systems, whereby vehicle owners can leverage their BEV battery as a backup power source, 42% of vehicle shoppers reported never having heard of the concept.

Key Points: 
  • When asked about vehicle-to-home (V2H) energy systems, whereby vehicle owners can leverage their BEV battery as a backup power source, 42% of vehicle shoppers reported never having heard of the concept.
  • Consumers demonstrate even lower levels of recognition for vehicle-to-grid (V2G) programs, which enable BEV owners to sell power back to the grid.
  • The report seeks to understand consumer expectations of BEV charging and the charging experiences of current BEV owners.
  • This points to a need for clear, concise messaging that emphasizes the longevity of BEV batteries and demonstrates how V2H and V2G programs can help BEV owners unlock new capabilities without compromising vehicle performance.

Quality and Styling Distinguish Top EV Models, but Public Charging Woes Felt by All, J.D. Power Finds

Retrieved on: 
Tuesday, February 27, 2024

Quality and cost of ownership have emerged as the top factors influencing satisfaction, according to the J.D.

Key Points: 
  • Quality and cost of ownership have emerged as the top factors influencing satisfaction, according to the J.D.
  • Both models rank highest in their respective segment on the strength of their performance in the vehicle quality and reliability factor.
  • Each model scores more than 60 points (on a 1,000-point scale) higher than their respective nearest segment competitor for that factor.
  • Following are key findings of the 2024 study:
    Public charging isn’t just bad—it’s getting worse: The study finds that the public charging experience continues to be a major source of EV owner frustration.

BYD Set to Challenge Tesla for the Crown in EV Sales in 2024, Says TrendForce

Retrieved on: 
Tuesday, February 20, 2024

TrendForce further notes that China remains the largest market for NEVs, commanding about 60% of the global market share.

Key Points: 
  • TrendForce further notes that China remains the largest market for NEVs, commanding about 60% of the global market share.
  • However, growth is slowing down due to a high base effect, and limited sales growth in other regions cannot compensate for the gap left by the Chinese market.
  • In 2023, Tesla continues to lead BEV rankings with a 19.9% market share, closely followed by BYD, which narrowed the sales gap with Tesla to 248,000 units.
  • TrendForce believes that BYD has the potential to challenge Tesla’s dominance in the BEV market this year.

IDTechEx Discusses Future Directions for the Green Hydrogen & Electrolyzer Market Growth

Retrieved on: 
Friday, March 8, 2024

This article provides an overview of some key drivers as well as future directions for the electrolyzer market.

Key Points: 
  • This article provides an overview of some key drivers as well as future directions for the electrolyzer market.
  • Water electrolyzer technologies for green hydrogen production and electrolyzer manufacturing & installation growth.
  • Certainly, growth in the electrolyzer market across all four electrolyzer types will be needed to meet ambitious national and regional targets for green and clean hydrogen production.
  • The new IDTechEx report, "Green Hydrogen Production & Electrolyzer Market 2024-2034: Technologies, Players, Forecasts", forecasts significant growth in the green hydrogen market, both in terms of project installations and electrolyzer manufacturing capacity, offering 10-year market forecasts in gigawatts (GW) of electrolyzer capacity and US$ billions (US$B) for the key electrolyzer technologies: AWE, PEMEL, AEMEL and SOEC.

IDTechEx Discusses Future Directions for the Green Hydrogen & Electrolyzer Market Growth

Retrieved on: 
Friday, March 8, 2024

This article provides an overview of some key drivers as well as future directions for the electrolyzer market.

Key Points: 
  • This article provides an overview of some key drivers as well as future directions for the electrolyzer market.
  • Together, fossil fuel-based production of hydrogen accounts for over 98% of all hydrogen produced, with low-carbon hydrogen (green and blue) occupying the small remaining share.
  • Certainly, growth in the electrolyzer market across all four electrolyzer types will be needed to meet ambitious national and regional targets for green and clean hydrogen production.
  • The new IDTechEx report, "Green Hydrogen Production & Electrolyzer Market 2024-2034: Technologies, Players, Forecasts", forecasts significant growth in the green hydrogen market, both in terms of project installations and electrolyzer manufacturing capacity, offering 10-year market forecasts in gigawatts (GW) of electrolyzer capacity and US$ billions (US$B) for the key electrolyzer technologies: AWE, PEMEL, AEMEL and SOEC.